Combination chemotherapy with DTIC (NSC 45388) in advanced malignant melanoma, soft tissue sarcomas, and Hodgkin's disease

G. Beretta, G. Bonadonna, E. Bajetta, G. Tancini, M. De Lena, A. Azzarelli, U. Veronesi

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The results of three controlled studies with multiple drug regimens which included DTIC are reported for advanced melanoma, soft tissue sarcomas, and Hodgkin's disease. In malignant melanoma, no statistical difference was observed between (a) DTIC, BCNU, and vincristine, and (b) DTIC, BCNU, and actinomycin D in terms of response rate, median duration of response, and survival. In sarcomas, the combination of adriamycin and DTIC produced a higher incidence of complete plus partial responders when compared to cyclophosphamide, vincristine, and methotrexate. However, no significant difference was seen in the median duration of response or survival. In Hodgkin's disease, a new four drug combination including adriamycin, bleomycin, vinblastine, and DTIC (ABVD) produced an incidence of complete remissions and a median duration of response comparable to that achieved with mechlorethamine, vincristine (Oncovin), prednisone, and procarbazine (MOPP). Preliminary data indicate that ABVD is not cross resistant to MOPP. It is concluded that DTIC can be successfully and safely employed in combination with conventional agents in susceptible neoplastic diseases.

Original languageEnglish
Title of host publicationCANCER TREAT.REP.
Pages205-211
Number of pages7
Volume60
Edition2
Publication statusPublished - 1976

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Combination chemotherapy with DTIC (NSC 45388) in advanced malignant melanoma, soft tissue sarcomas, and Hodgkin's disease'. Together they form a unique fingerprint.

Cite this